Personen

TOP 5 Publikationen:

1. Schmidt-Kraepelin C, Feyerabend S, Engelke C, Riesbeck M, Meisenzahl-Lechner E, Verde PE, Correll CU, Kluge M, Makiol C, Neff A, Lange C, Englisch S, Zink M, Langguth B, Poeppl TB, Reske D, Gouzoulis-Mayfrank E, Gründer G, Hasan A, Brockhaus-Dumke A, Jäger M, Baumgärtner J, Leucht S, Cordes J, COMBINE Study Group . Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.Lancet Psychiatry. 2022 9(4):291-306.
2. Weinbrenner A, Peus V, Inta D, Englisch S, Zink M. Risperidone-associated increase in triglyceride levels.Am J Psychiatry. 2009 166(1):113-4.
3. Zink M, Englisch S. Schizophrenia treatment: an obstacle course.Lancet Psychiatry. 2016 3(4):310-12. Epub 2016 Feb 24.
4. Schirmbeck F, Rausch F, Englisch S, Eifler S, Esslinger C, Meyer-Lindenberg A, Zink M. Stable Cognitive Deficits in Schizophrenia Patients With Comorbid Obsessive-Compulsive Symptoms: A 12-Month Longitudinal Study.Schizophr Bull. 2013 39(6):1261-71. Epub 2012 Oct 27.
5. Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.Psychol Med. 2011 41(11):2361-73.